Paladate Bio Insider Buy Signals Confidence Ahead of Crohn’s NDA FilingPalaisade Bio insider buy signals confidence in its Phase III Crohn’s drug; watch for FDA filing and market launch in 2026.Palisade Bio Inc Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated DirectorDealingsBot 14/01/2026, 03:58 4 minutes to read
